FDA Brief

Warning letters Drugs

FDA warning letter to

Atlantic Management Resources LTD dba. Claire Ellen Products

MediumIssued Jan 20, 2023Posted Mar 14, 2023Division of Pharmaceutical Quality Operations I

Atlantic Management Resources (Claire Ellen Products) had CGMP violations and distributed unlisted Neuroquell Plus Cream.

What happened

FDA inspected the Westborough, MA drug manufacturing facility from July 26 to August 10, 2022. Investigators found no adequate quality unit or written quality procedures, no monitoring of storage conditions, and no batch production records. FDA also found Neuroquell Plus Cream was distributed under the firm’s name but was not listed with FDA.

What FDA found

  1. The firm lacked an adequate quality unit and written quality procedures to oversee drug manufacturing.

    21 CFR 211.22(a) and (d)
  2. It did not store drug products under appropriate temperature, humidity, and light conditions, including for a heat-, sunlight-, and moisture-sensitive bulk drug.

    21 CFR 211.142(b)
  3. It had no batch production and control records or batch numbers documenting each manufacturing step.

    21 CFR 211.188(b)
  4. Neuroquell Plus Cream was distributed under the firm’s own name and label but was not listed with FDA.

    FD&C Act section 510(j)(1); 21 CFR 207.41; 21 CFR 207.49(a)(5)

What FDA wants

FDA asks the firm to respond in writing within 15 working days, identify what it has done to correct violations and prevent recurrence, and confirm whether it intends to resume drug manufacturing. If it resumes, FDA says it must notify the office first, resolve all deficiencies, and engage a qualified consultant to perform a six-system CGMP audit.

Who should pay attention

  • companies that distribute drugs under their own label
  • brands using contract manufacturers or suppliers
  • retailers or pharmacies selling homeopathic drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk